<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Jonathan</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Peter</forename><forename type="middle">H</forename><surname>O'donnell</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Arjun</forename><forename type="middle">V</forename><surname>Balar</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Bradley</forename><forename type="middle">A</forename><surname>Mcgregor</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Elisabeth</forename><forename type="middle">I</forename><surname>Heath</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Evan</forename><forename type="middle">Y</forename><surname>Yu</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Matthew</forename><forename type="middle">D</forename><surname>Galsky</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Noah</forename><forename type="middle">M</forename><surname>Hahn</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Elaina</forename><forename type="middle">M</forename><surname>Gartner</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PA-C, MMSc</roleName><forename type="first">Juan</forename><forename type="middle">M</forename><surname>Pinelli</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Ying</forename><surname>Liang</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Amal</forename><surname>Melhem-Bertrandt</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Daniel</forename><forename type="middle">P</forename><surname>Petrylak</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Rosenberg</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Honoraria</forename><forename type="middle">:</forename><surname>Merck</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Genentech</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MedImmune</roleName><surname>Astrazeneca</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Janssen</forename><surname>Pharmaceuticals</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Merck, AstraZeneca, EMD Serono, Incyte, Amgen, Tolmar, QED</roleName><surname>Bayer</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Therapeutics</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noah</forename><forename type="middle">M</forename><surname>Hahn Honoraria</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shang-Ying</forename><surname>Liang</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Consulting or Advisory Role: Genentech</orgName>
								<orgName type="institution">EMD Serono</orgName>
								<address>
									<addrLine>Cerulean Pharma, AstraZeneca, MedImmune, Astellas Pharma</addrLine>
									<settlement>Merck, Pfizer, Incyte, Seattle Genetics, Nektar</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="laboratory">Inst), Celldex (Inst), Inovio Pharmaceuticals (Inst), Celgene (Inst), Zenith Epigenetics (Inst), Merck (Inst), AstraZeneca (Inst), Esanik (Inst), Oncolys BioPharma (Inst), Curemeta (Inst), Bristol-Myers Squibb (Inst), eFFECTOR Therapeutics (Inst), Fortis (Inst), Astellas Pharma (Inst), Medivation (Inst), Ignyta (Inst), Synta (Inst), Caris Life Sciences (Inst), Boehringer Ingelheim (Inst), GlaxoSmithKline (Inst), Merck Sharp &amp; Dohme (Inst), Plexxikon (Inst), Corcept Therapeutics (Inst</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Dendreon, Seattle Genetics</orgName>
								<orgName type="department" key="dep2">Seattle Genetics (Inst)</orgName>
								<orgName type="laboratory">Pharmacyclics Research Funding: Agensys (Inst), Astellas Pharma (Inst), Dendreon (Inst), Genentech (Inst), Bayer (Inst), Merck (Inst)</orgName>
								<address>
									<country>Daiichi Sankyo</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="laboratory">Bristol-Myers Squibb, AstraZeneca, MedImmune, Pieris Pharmaceuticals, Inovio Pharmaceuticals, Genentech, Health Advances, Merck, Ferring, Principia Biopharma, Champions Oncology, Taris BioMedical, Seattle Genetics, Astellas Pharma, Incyte, TransMed, Rexahn Pharmaceuticals, CicloMed, Janssen Pharmaceuticals Research Funding: Genentech (Inst), Merck (Inst), Bristol-Myers Squibb (Inst), AstraZeneca (Inst), MedImmune (Inst), Principia Biopharma (Inst), Acerta Pharma (Inst), Incyte (Inst), Seattle Genetics (Inst), Astellas Pharma (Inst), Astex Pharmaceuticals (Inst), Pieris Pharmaceuticals (Inst)</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Myers Squibb, Clovis Oncology, Incyte, Janssen Pharmaceuticals, Pharmacyclics, Seattle Genetics, Urogen Pharma Research Funding: Progenics (Inst), Sanofi (Inst)</orgName>
								<orgName type="department" key="dep2">Seattle Genetics (Inst)</orgName>
								<orgName type="department" key="dep3">Clovis Oncology (Inst)</orgName>
								<orgName type="department" key="dep4">Ada Cap (Inst)</orgName>
								<orgName type="laboratory">Endocyte (Inst), Genentech (Inst), Merck (Inst), Astellas Medivation (Inst), Novartis (Inst), AstraZeneca (Inst), Bayer (Inst), Eli Lilly (Inst), Innocrin Pharma (Inst), MedImmune (Inst), Pfizer (Inst)</orgName>
								<address>
									<addrLine>Roche (Inst)</addrLine>
									<settlement>Bristol-Myers Squibb (Inst)</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1200/JCO.19</idno>
					<note type="submission">Accepted on May 24, 2019 and published</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Genentech (Inst)</term>
					<term>Oncogenex (Inst)</term>
					<term>Agensys (Inst)</term>
					<term>Mirati Therapeutics (Inst)</term>
					<term>Novartis (Inst)</term>
					<term>Viralytics (Inst)</term>
					<term>Genentech (Inst)</term>
					<term>Incyte (Inst)</term>
					<term>Seattle Genetics (Inst)</term>
					<term>Bayer (Inst)</term>
					<term>AstraZeneca (Inst)</term>
					<term>QED (Inst) Patents</term>
					<term>Royalties</term>
					<term>Other Intellectual Property: Predictor of platinum sensitivity (Inst) Travel</term>
					<term>Accommodations</term>
					<term>Expenses: Genentech</term>
					<term>Bristol-Myers Squibb Allergan</term>
					<term>PrescriptIQ Honoraria: Genentech</term>
					<term>Merck</term>
					<term>AstraZeneca</term>
					<term>Astellas Pharma</term>
					<term>Seattle Genetics</term>
					<term>Inovio Pharmaceuticals</term>
					<term>Janssen Biotech</term>
					<term>Parexel</term>
					<term>Kantar Health</term>
					<term>Harrison Consulting Group</term>
					<term>Quintiles</term>
					<term>OncLive Consulting or Advisory Role: Merck Research Funding: Boehringer Ingelheim (Inst)</term>
					<term>Merck (Inst)</term>
					<term>Genentech (Inst)</term>
					<term>AstraZeneca (Inst)</term>
					<term>MedImmune (Inst)</term>
					<term>Acerta Pharma (Inst)</term>
					<term>Janssen Pharmaceuticals (Inst)</term>
					<term>Seattle Genetics (Inst)</term>
					<term>Bristol-Myers Squibb (Inst) Patents</term>
					<term>Royalties</term>
					<term>Other Intellectual Property: Coinventor on a pending patent for a genomic prescribing system for medication prescribing Travel</term>
					<term>Accommodations</term>
					<term>Expenses: Merck</term>
					<term>Seattle Genetics</term>
					<term>Astellas Pharma Other Relationship: Advance Medical</term>
					<term>Janssen Pharmaceuticals Merck (Inst)</term>
					<term>Genentech (Inst)</term>
					<term>AstraZeneca (Inst)</term>
					<term>MedImmune (Inst)</term>
					<term>Seattle Genetics Bayer</term>
					<term>Seattle Genetics</term>
					<term>Astellas Pharma</term>
					<term>Exelixis</term>
					<term>AstraZeneca</term>
					<term>Genentech</term>
					<term>Nektar</term>
					<term>Janssen Oncology</term>
					<term>Pfizer</term>
					<term>EMD Serono Research Funding: Bristol-Myers Squibb (Inst)</term>
					<term>Exelixis (Inst)</term>
					<term>Calithera Biosciences (Inst)</term>
					<term>Seattle Genetics (Inst)</term>
					<term>Astellas Pharma (Inst) Bayer</term>
					<term>Dendreon</term>
					<term>Sanofi</term>
					<term>Seattle Genetics</term>
					<term>Agensys Speakers&apos; Bureau: Sanofi Research Funding: Tokai Pharmaceuticals (Inst)</term>
					<term>Seattle Genetics (Inst)</term>
					<term>Agensys (Inst)</term>
					<term>Dendreon (Inst)</term>
					<term>Genentech (Inst)</term>
					<term>Millennium Pharmaceuticals Rappta Therapeutics Consulting or Advisory Role: BioMotiv</term>
					<term>Janssen Pharmaceuticals</term>
					<term>Dendreon</term>
					<term>Merck</term>
					<term>GlaxoSmithKline</term>
					<term>Eli Lilly</term>
					<term>Astellas Pharma</term>
					<term>Genentech</term>
					<term>Bristol-Myers Squibb</term>
					<term>Novartis</term>
					<term>Pfizer</term>
					<term>EMD Serono</term>
					<term>AstraZeneca</term>
					<term>Seattle Genetics</term>
					<term>Incyte</term>
					<term>Aileron Therapeutics</term>
					<term>Dracen</term>
					<term>Inovio Pharmaceuticals</term>
					<term>NuMab</term>
					<term>Dragonfly Therapeutics Research Funding: Janssen Oncology (Inst)</term>
					<term>Dendreon (Inst)</term>
					<term>Novartis (Inst)</term>
					<term>Bristol-Myers Squibb (Inst)</term>
					<term>Merck (Inst)</term>
					<term>AstraZeneca (Inst)</term>
					<term>Genentech (Inst) Patents</term>
					<term>Royalties</term>
					<term>Other Intellectual Property: Methods and compositions for treating cancer and related methods; application number: 20120322792 Seattle Genetics</term>
					<term>Astellas Pharma Stock and Other Ownership Interests: Seattle Genetics</term>
				</keywords>
			</textClass>
			<abstract>
				<p>PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial carcinoma. METHODS EV-201 is a global, phase II, single-arm study of enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle) in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti-PD-1/L1 therapy. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review. Key secondary end points were duration of response, progression-free survival, overall survival, safety, and tolerability. RESULTS Enfortumab vedotin was administered to 125 patients with metastatic urothelial carcinoma. Median follow-up was 10.2 months (range, 0.5 to 16.5 months). Confirmed objective response rate was 44% (95% CI, 35.1% to 53.2%), including 12% complete responses. Similar responses were observed in prespecified subgroups, such as those patients with liver metastases and those with no response to prior anti-PD-1/L1 therapy. Median duration of response was 7.6 months (range, 0.95 to 11.301 months). The most common treatment-related adverse events were fatigue (50%), any peripheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%), and dysgeusia (40%). No single treatment-related adverse events grade 3 or greater occurred in 10% or more of patients. CONCLUSION Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti-PD-1/L1 therapies.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>Locally advanced or metastatic urothelial carcinoma of the renal pelvis, ureters, bladder, or urethra is an incurable disease with poor long-term survival. <ref type="bibr">1</ref> Platinum-based therapies are the first-line treatment for most patients, with objective response rates of 41% to 50% and median progression-free survival of 7.6 months. <ref type="bibr" target="#b6">[2]</ref><ref type="bibr" target="#b7">[3]</ref><ref type="bibr" target="#b8">[4]</ref> In the postplatinum setting, phase III studies of anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy demonstrated objective response rates of 21% and 13%, respectively, with an overall survival advantage compared with second-line chemotherapy demonstrated in one of two studies conducted to date. <ref type="bibr" target="#b9">5,</ref><ref type="bibr" target="#b10">6</ref> For patients who have experienced progression after platinum-based therapy and anti-PD-1/L1 therapy, treatment options are limited to chemotherapies that have modest activity. <ref type="bibr">7</ref> Thus, there is an urgent need for effective and tolerable therapies in patients with locally advanced and metastatic urothelial carcinoma after treatment with platinum and anti-PD-1/L1 therapies.</p><p>Enfortumab vedotin is an investigational antibodydrug conjugate that is comprised of a fully human monoclonal antibody conjugated to the clinically validated microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable linker. <ref type="bibr" target="#b12">8,</ref><ref type="bibr" target="#b13">9</ref> Enfortumab vedotin targets Nectin-4, a transmembrane protein that belongs to the Nectin family of cell adhesion molecules involved in cellular processes associated with oncogenesis. <ref type="bibr" target="#b12">8,</ref><ref type="bibr" target="#b14">[10]</ref><ref type="bibr" target="#b15">[11]</ref><ref type="bibr" target="#b16">[12]</ref> Nectin-4 is highly expressed in several solid tumors, including urothelial, breast, gastric, and lung carcinomas. Expression is weak to moderate in normal skin. <ref type="bibr" target="#b12">8,</ref><ref type="bibr" target="#b17">[13]</ref><ref type="bibr" target="#b18">[14]</ref><ref type="bibr" target="#b19">[15]</ref><ref type="bibr" target="#b20">[16]</ref> Enfortumab vedotin binds to cells that express Nectin-4 with high affinity, triggering the internalization and release of MMAE in target cells. MMAE disrupts microtubule networks, leading to cell-cycle arrest and apoptotic death of Nectin-4-expressing cells.</p><p>The phase I dose escalation and expansion study EV-101 (ClinicalTrials.gov identifier: NCT02091999) demonstrated that enfortumab vedotin, administered on days 1, 8, and 15 of every 28-day cycle, has antitumor activity in previously treated patients with metastatic urothelial carcinoma, including those who received platinum-based chemotherapy and anti-PD-1/L1 therapy. <ref type="bibr" target="#b21">17</ref> Pharmacokinetic data from this study demonstrate a half-life of approximately 2 days, which supports this dosing schedule. <ref type="bibr" target="#b22">18</ref> EV-201, a two-cohort, single-arm, phase II study, was designed to establish the efficacy and safety of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with anti-PD-1/L1 therapy. Cohort 1 enrolled patients who were previously treated with both platinum chemotherapy and an anti-PD-1/L1 therapy, whereas Cohort 2 continues to enroll patients who were previously treated only with an anti-PD-1/L1 therapy. Here, we report results from EV-201 Cohort 1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Participants</head><p>Patients with locally advanced or metastatic urothelial carcinoma who were previously treated with anti-PD-1/ L1 therapy and age 18 years or older were eligible to enroll if they experienced progression during or after their most recent therapy, had an Eastern Cooperative Oncology Group performance status score of 1 or less, and had adequate baseline organ function. Patients with ongoing sensory or motor neuropathy grade 2 or greater, active CNS metastases, or uncontrolled diabetes were excluded. Uncontrolled diabetes was defined as hemoglobin A1C of 8% or greater or hemoglobin A1C of 7% to less than 8% with associated diabetes symptomspolyuria or polydipsia-that were not otherwise explained. There were no limits for prior lines of therapy, including taxanes. Full eligibility criteria are available in the protocol (Data Supplement). patients were discontinued from the study before receiving study treatment; 1 due to clinical deterioration, 1 per patient decision, and 1 due to low hemoglobin levels after screening and enrollment. This latter patient met all eligibility criteria, including adequate hemoglobin level and was enrolled in the study; however, the patient's hemoglobin levels were subsequently found to be low and the investigator withdrew the patient from the study as a result.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial Design</head><p>EV-201 is a global, single-arm, two-cohort, phase II multicenter study that was designed to assess the efficacy and safety of enfortumab vedotin <ref type="figure" target="#fig_0">(Fig 1)</ref>. Cohort 1 enrolled platinum-and anti-PD-1/L1-treated patients with Eastern Cooperative Oncology Group performance status scores of 1 or less. Platinum treatment was defined as platinum-containing chemotherapy in the neoadjuvant and/or adjuvant setting with recurrent or progressive disease within 12 months of completion, or platinum in the locally advanced or metastatic setting.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment</head><p>Patients received enfortumab vedotin 1.25 mg/kg intravenously over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. Weight-based dosing was calculated using the patient's actual body weight, with a maximum dose of 125 mg. Dose modifications were permitted to manage treatment-related hematologic and nonhematologic toxicities and are outlined in the protocol (Data Supplement). Treatment continued until disease progression, unacceptable toxicity, consent withdrawal, or investigator decision. Additional details are provided in the protocol.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments</head><p>Efficacy of enfortumab vedotin was assessed by appropriate imaging (computed tomography or magnetic resonance imaging) every 8 weeks (6 1 week), then every 12 weeks (6 1 week) after 1 year. Time points for response assessments were calculated from cycle 1, day 1. Complete or partial responses, as defined by RECIST version 1.1, <ref type="bibr" target="#b23">19</ref> were confirmed with repeat scans 4 to 5 weeks after initial response and assessed by blinded independent central review (BICR) and investigator.</p><p>Safety assessments included physical and eye examinations, routine chemistry, and hematologic laboratory tests. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Per protocol, certain adverse events observed in the EV-201 study were prespecified for assessment and analysis as composite terms and were observed until resolved, returned to baseline, or became chronic and adequately characterized. These events are summarized here in composite terms of peripheral neuropathy, rash, infusion-related reactions, and hyperglycemia. Expression levels of Nectin-4 and PD-L1 were assessed using validated immunohistochemical assays in archival or fresh tumor samples (Data Supplement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>End Points</head><p>The Primary end point was confirmed objective response rate as assessed by BICR. Data cutoff was to be at least 6 months after the last patient in Cohort 1 received his or her first dose. Key secondary end points were duration of response and progression-free survival by BICR and investigator; objective response rate by investigator; and overall survival, safety, and tolerability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial Oversight</head><p>The EV-201 trial was designed by the sponsors, with contributions from a steering committee of study investigators. Study protocol and amendments were approved by site independent review boards or ethics committees and conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Committee on Harmonization. Written informed consent was obtained from all patients. Safety was monitored by an independent data-monitoring committee and the sponsor.</p><p>Data were analyzed by sponsor statisticians and interpreted by authors and the sponsor.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p>Objective response rate and its two-sided 95% CI were calculated using the Clopper-Pearson method. For timeto-event end points, median survival time was estimated using the Kaplan-Meier method and the associated 95% CI was calculated using the complementary log-log transformation.</p><p>With 100 patients in Cohort 1, there is a 98% chance of observing ORR with lower-limit of the exact 95% CI excluding a historical response rate of 10%, <ref type="bibr" target="#b24">20</ref> if the true ORR is 25%. The complete statistical analysis plan is available along with the protocol in the Data Supplement.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Participants</head><p>There  <ref type="figure">(Fig 2A)</ref>. Investigator-assessed responses, including objective response rate, duration of response, tumor reduction, and progression-free survival, were similar to those assessed by BICR (Data Supplement; Appendix <ref type="table" target="#tab_2">Table A2</ref>, online only; and Appendix Figs A2, A3, and A4, online only).</p><p>Responses across all subgroups analyzed were consistent with overall study results. Objective responses occurred regardless of patients' responses to prior anti-PD-1/L1 therapy (56% in responders and 41% in nonresponders). Similar responses were observed in patients with poor prognostic characteristics, including liver metastases (38%), and three or more prior lines of therapy (41%; <ref type="figure" target="#fig_4">Fig 3)</ref>.</p><p>Target lesions were reduced in a majority of evaluable patients (84%; <ref type="figure">Fig 2B)</ref>. Estimated median progression-free survival was 5.8 months (95% CI, 4.9 to 7.5 months; Appendix <ref type="figure">Fig</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p>The most common treatment-related adverse events were fatigue (50% all grade and 6% grade $ 3), alopecia (49% all grade), decreased appetite (44% all grade and 1% grade $ 3), dysgeusia (40% all grade and none grade $ 3), and peripheral sensory neuropathy (40% all grade and 2% grade $ 3; <ref type="table" target="#tab_7">Table 3</ref>). The most common grade 3 or greater treatment-related adverse events were neutropenia (8%), anemia (7%), and fatigue (6%). Febrile neutropenia (4%) was the most common serious treatment-related adverse event; there was no routine growth factor use. A full listing of adverse events is available in <ref type="table" target="#tab_7">Appendix Tables A3 and A4</ref> (online only). Treatment-related adverse events led to dose reductions in 32% of patients and discontinuation in 12% of patients. Peripheral sensory neuropathy was the most common treatment-related adverse event that led to dose reduction (9%) and discontinuation (6%). Peripheral neuropathy, rash, hyperglycemia, and infusion-related reactions were prespecified for analysis as composite terms (Appendix <ref type="table" target="#tab_11">Table A5</ref>, online only). A summary of time to onset and time to resolution for these events is available in Appendix <ref type="table" target="#tab_20">Table A6</ref> (online only). Treatment-related peripheral neuropathy occurred in 50% of patients, almost all (94%) of which were grade 2 or less. Peripheral sensory neuropathy was more common (44%) than motor neuropathy (14%). Of the 42 patients with peripheral neuropathy at enrollment, 20 (48%) did not experience worsening from baseline. Most patients (76%) with peripheral neuropathy had resolution or ongoing grade 1 peripheral neuropathy at last follow-up.</p><p>Treatment-related rash-as a composite term-occurred in 48% of patients, most of which were low grade (75% grade # 2) with onset in the first treatment cycle. Two patients discontinued treatment as a result of rash, one of whom experienced a grade 3 rash reported as Stevens-Johnson syndrome. Onset of symptoms for this event was 4 days after the initial dose and the rash resolved after the discontinuation of enfortumab vedotin and treatment with systemic corticosteroids. Of all patients who experienced rash, 73% experienced complete resolution and 20% had some improvement at last follow-up. Most patients (75%) with ongoing rash had grade 1 at last follow-up. Three patients had infusion site extravasation, of which two cases were considered serious. All patients with extravasation recovered completely and were able to continue treatment.</p><p>Treatment-related hyperglycemia occurred in few patients (11%), regardless of known hyperglycemia at baseline. Nineteen patients had hyperglycemia at baseline and, of these, 68% did not develop treatment-related events. Of patients without hyperglycemia at baseline, 8% developed treatment-related hyperglycemia. Hyperglycemia in seven of 14 patients with these events was grade 2 or less. The single patient with grade 4 hyperglycemia did not have known baseline hyperglycemia and, per protocol, treatment was discontinued. The patient later recovered and had no ongoing need for insulin or oral hypoglycemic agents. This was the only discontinuation as a result of hyperglycemia. Among patients who experienced hyperglycemia, 57% achieved complete resolution and 14% experienced some improvement.</p><p>There were no treatment-related deaths during the 30-day safety reporting period. One death as a result of interstitial lung disease that occurred outside the safety reporting period was reported as treatment related. This death was confounded by prolonged high-dose corticosteroid use and suspected Pneumocystis jiroveci pneumonia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>In patients with metastatic urothelial carcinoma who were previously treated with both platinum chemotherapy and anti-PD-1/L1 therapy, enfortumab vedotin treatment led to a 44% objective response rate, including a 12% complete response rate and a 7.6-month duration of response. Most responses to enfortumab vedotin occurred rapidly.  *ECOG performance status scale ranges from 0 to 5, with 0 indicating that the patient is fully active with no restrictions, 1 that the patient is ambulatory and able to carry out work of a light or sedentary nature but restricted in physically strenuous activity, and higher numbers indicating greater disability.</p><p>†Including renal pelvis, ureter, and kidney. ‡A patient may have metastatic disease in more than one location. §Including anti-PD-1/L1-containing therapy in the neoadjuvant/ adjuvant setting with progression or recurrence within 3 months after therapy completion, or platinum-based therapy in the neoadjuvant/ adjuvant setting with progression or recurrence within 12 months after therapy conclusion.</p><p>kFive patients did not have tumor samples evaluable for PD-L1 or Nectin-4 expression levels.</p><p>¶Nectin-4 levels were assessed by immunohistochemistry in tumor biopsies. Although this was a single-arm study, which limits interpretation, responses observed here with enfortumab vedotin were remarkably consistent with the prior phase I study EV-101. <ref type="bibr" target="#b21">17</ref> In the control arms of recent randomized phase III trials in the postplatinum setting, objective response rates in patients who were treated with antimicrotubule agents ranged from 11% to 13%, including 3% complete responses. <ref type="bibr" target="#b9">5,</ref><ref type="bibr" target="#b10">6</ref> Unlike these phase III trials, which primarily enrolled patients with only prior platinum therapy, patients who received enfortumab vedotin in this study were more heavily pretreated, with one half of patients receiving three or more lines of therapy, one of which was an anti-PD-1/L1 therapy. In a subset of patients who were previously treated with both platinum and anti-PD-1/L1 therapy from a randomized phase III trial, docetaxel had a 10.5% response rate. <ref type="bibr" target="#b27">23</ref> Although the single-arm nature of EV-201 limits the ability to compare the activity of enfortumab vedotin with standard antimicrotubule chemotherapy, differences in observed response rates (44%) and complete response rates (12%), as well as the consistent results across EV-101 and EV-201, suggest that enfortumab vedotin possesses  antitumor effects significantly beyond conventional chemotherapy. In fact, the objective response rate of enfortumab vedotin monotherapy in this study is similar to that of gemcitabine and carboplatin in the first-line setting, which suggests that treatment earlier in the disease course should be explored in clinical trials. <ref type="bibr" target="#b7">3</ref> Enfortumab vedotin also had consistent clinical activity across all subgroups analyzed, including patients with traditionally challenging features, such as liver metastases or other poor prognostic factors. Responses were observed regardless of previous response to anti-PD-1/L1 therapy. These data demonstrate the ability of enfortumab vedotin to elicit responses across a broad range of patients with different disease characteristics.  vedotin dose reductions and delays. Nearly all patients with rash had resolution or improvement and most ongoing treatment-related rashes were grade 1 at last follow-up. The one reported case of Stevens-Johnson syndrome may have been confounded by the direct effects of enfortumab vedotin on Nectin-4 in skin. Hyperglycemia was much less common than rash or peripheral neuropathy, and most patients experienced resolution or improvement at last follow-up. Treatment-related hyperglycemia occurred regardless of known hyperglycemia at baseline and the underlying etiology remains unclear but is not likely to be an on-target effect.</p><p>An ongoing phase III trial comparing enfortumab vedotin monotherapy with single-agent chemotherapy in patients with prior platinum and anti-PD-1/L1 therapy may establish the survival benefit of enfortumab vedotin in this patient population (EV-301; ClinicalTrials.gov identifier: NCT03474107). The EV-201 study is also actively enrolling a second cohort (Cohort 2) of patients who have received prior anti-PD-1/L1 therapy and are cisplatin ineligible without prior platinum treatment to determine if a similar benefit will be observed. In addition, enfortumab vedotin is being evaluated in a broader population of patients with urothelial carcinoma, including in the first-line setting where it is being studied in combination with anti-PD-1 and/or platinum-based therapies (EV-103; ClinicalTrials.gov identifier: NCT03288545). In this study, enfortumab vedotin is administered on days 1 and 8 of a 21-day cycle to coincide with the administration of the other agents. Nectin-4 is also expressed in other tumor types, and enfortumab vedotin may be explored in other solid tumors. <ref type="bibr" target="#b12">8</ref> In conclusion, enfortumab vedotin is the first antibody-drug conjugate targeting Nectin-4 in clinical development, and the antitumor activity observed in EV-201 validates Nectin-4 as a therapeutic target in urothelial carcinoma. In Cohort 1 patients who previously received platinum and anti-PD-1/L1 therapies, enfortumab vedotin has a 44% objective response rate and a 12% complete response rate. Data reported here demonstrate that enfortumab vedotin has the potential to change the treatment landscape of metastatic urothelial carcinoma.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AFFILIATIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Patient populations for analysis. The full analysis set <ref type="bibr">(FAS)</ref> included all patients who were enrolled in the study who received any amount of enfortumab vedotin. The FAS was used as the primary analysis set for efficacy end points. The safety analysis set included all patients who received any amount of enfortumab vedotin and was therefore used for all safety analyses.</p><p>Biomarker assessments. Samples for exploratory biomarkers were collected at protocol-specified timepoints defined in the schedule of events. Biomarker assessments were not used for patient selection. Programmed death ligand 1 levels were assessed in tumor-infiltrating immune cells using DAKO 22C3 immunohistochemistry to determine PD-L1 combined positive score of less than 10 versus 10 or greater in archival or fresh tumor samples. Overall, 78 (65%) of 120 evaluable patients had a programmed death ligand 1 combined positive score of less than 10.    <ref type="formula">2 3 4 5 6 7 8   11 12 13 14 15 16 17 18  9</ref>Time (months) Progression-Free Survival (%)             †Improvement defined as at least one grade improvement from the worst grade at the last assessment. ‡Resolution defined as a return to baseline grade or better at the last assessment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Responders Without</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIG 1 .</head><label>1</label><figDesc>CONSORT diagram. Three</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>A5, online only), and estimated median overall survival was 11.7 months (95% CI, 9.1 months to not reached; AppendixFig A6, online only).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>Immunohistochemistry images were scored by a pathologist using the H-score method (H-score = [percentage of strong positive tumor cells 3 3] + [percentage of moderate positive tumor cells 3 2] + [percentage of weak positive tumor cells 3 1]). A score of 0 indicates no expression and a score of 300 indicates the maximum possible expression with this assay.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIG 3 .</head><label>3</label><figDesc>Objective response in key prespecified subgroups per blinded independent central review. This prespecified subgroup analysis was performed on the full analysis set of all patients who received any amount of enfortumab vedotin (N = 125). Historical control response rate is 10%, as indicated by dashed line. 20 The programmed death ligand 1 (PD-L1) combined positive score (CPS) was defined as the percentage of tumor and infiltrating immune cells with PD-L1 expression of the total number of tumor cells. The upper tract was defined as the renal pelvis, ureter, and kidney. Data are given as No. (%), unless otherwise noted. ( †) Bellmunt risk score was not available for 1 patient. ( ‡) Anti-PD-1 or anti-PD-L1 therapy. ( §) Five patients did not have tumor samples evaluable for PD-L1 expression levels. ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; UC, urothelial carcinoma.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Nectin- 4</head><label>4</label><figDesc>levels were assessed by immunohistochemistry in tumor biopsies. Immunohistochemistry images were scored by a pathologist using the H-score method (H-score = [percentage of strong positive tumor cells 3 3] + [percentage of moderate positive tumor cells 3 2] + [percentage of weak positive tumor cells 3 1]). All evaluable patients (120 of 120) had detectable Nectin-4 on archival or fresh tumor samples by immunohistochemistry as determined by H-score. Nectin-4 expression was high, with a median H-score of 290 (range, 14 to 300).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>FIG A3 .</head><label>A3</label><figDesc>Kaplan-Meier estimate of duration of response for responders per blinded independent central review. PD, progressive disease. Waterfall plot of the best percentage change from baseline of target lesions per investigator. Waterfall plot of the best percentage of change from baseline in the sum of the diameters of target lesions according to</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>FIG</head><label></label><figDesc>A4. Kaplan-Meier estimate of progression-free survival per investigator in the full analysis set. 0 1</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>FIGFIG</head><label></label><figDesc>A5. Kaplan-Meier estimate of progression-free survival per blinded independent central review in the full analysis set. A6. Kaplan-Meier estimate of overall survival in the full analysis set.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 1 .</head><label>1</label><figDesc>Demographic and Disease Characteristics at Baseline</figDesc><table><row><cell></cell><cell>Patients</cell></row><row><cell>Characteristic</cell><cell>(N = 125)</cell></row><row><cell>Male sex</cell><cell>88 (70)</cell></row><row><cell>Age, years</cell><cell></cell></row><row><cell>Median</cell><cell>69</cell></row><row><cell>Min, max</cell><cell>40, 84</cell></row><row><cell>Age group, years</cell><cell></cell></row><row><cell>, 75</cell><cell>91 (73)</cell></row><row><cell>$ 75</cell><cell>34 (27)</cell></row><row><cell>Region</cell><cell></cell></row><row><cell>North America</cell><cell>117 (94)</cell></row><row><cell>Asia</cell><cell>8 (6)</cell></row><row><cell>ECOG performance status*</cell><cell></cell></row><row><cell>0</cell><cell>40 (32)</cell></row><row><cell>1</cell><cell>85 (68)</cell></row><row><cell>Primary tumor location</cell><cell></cell></row><row><cell>Bladder/other</cell><cell>81 (65)</cell></row><row><cell>Upper tract †</cell><cell>44 (35)</cell></row><row><cell>Histology type</cell><cell></cell></row><row><cell>Urothelial carcinoma only</cell><cell>84 (67)</cell></row><row><cell>Urothelial carcinoma with</cell><cell>15 (12)</cell></row><row><cell>squamous differentiation</cell><cell></cell></row><row><cell>Urothelial carcinoma with</cell><cell>26 (21)</cell></row><row><cell>other histologic variants</cell><cell></cell></row><row><cell>Current extent of disease</cell><cell></cell></row><row><cell>Metastatic</cell><cell>125 (100)</cell></row><row><cell>Metastasis sites</cell><cell></cell></row><row><cell>Lymph nodes only</cell><cell>13 (10)</cell></row><row><cell>Visceral disease ‡</cell><cell>112 (90)</cell></row><row><cell>Bone</cell><cell>51 (41)</cell></row><row><cell>Liver</cell><cell>50 (40)</cell></row><row><cell>Lung</cell><cell>53 (42)</cell></row><row><cell>No. of prior systemic therapies</cell><cell></cell></row><row><cell>in locally advanced or metastatic setting §</cell><cell></cell></row><row><cell>Median</cell><cell>3</cell></row><row><cell>Min, max</cell><cell>1, 6</cell></row><row><cell>$ 3</cell><cell>63 (50)</cell></row><row><cell>Best response to PD-1/L1-</cell><cell></cell></row><row><cell>containing therapy</cell><cell></cell></row><row><cell>Responder</cell><cell>25 (20)</cell></row><row><cell>Nonresponder</cell><cell>100 (80)</cell></row><row><cell>PD-L1 status by combined</cell><cell></cell></row><row><cell>positive scorek</cell><cell></cell></row><row><cell>, 10</cell><cell>78/120 (65)</cell></row><row><cell>$ 10</cell><cell>42/120 (35)</cell></row><row><cell>(continued on following page)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 2 .</head><label>2</label><figDesc>Summary of Responses Per Blinded Independent Central Pearson method.<ref type="bibr" target="#b26">22</ref> †Best overall response according to RECIST v1.1. ‡Includes 10 patients who did not have any response assessment postbaseline, one patient who had uninterpretable postbaseline assessment, and one patient whose postbaseline assessment did not meet the minimum interval requirement for stable disease.</figDesc><table><row><cell>Review</cell><cell></cell></row><row><cell>Response</cell><cell>Patients (N = 125)</cell></row><row><cell>Objective response rate</cell><cell>55 (44)</cell></row><row><cell>95% CI*</cell><cell>35.1 to 53.2</cell></row><row><cell>Best overall response †</cell><cell></cell></row><row><cell>Complete response</cell><cell>15 (12)</cell></row><row><cell>Partial response</cell><cell>40 (32)</cell></row><row><cell>Stable disease</cell><cell>35 (28)</cell></row><row><cell>Progressive disease</cell><cell>23 (18)</cell></row><row><cell>Not evaluable ‡</cell><cell>12 (10)</cell></row><row><cell>NOTE. Data are presented as No. (%).</cell><cell></cell></row><row><cell>*Computed using the Clopper-</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 1 .</head><label>1</label><figDesc>Demographic and Disease Characteristics at Baseline</figDesc><table><row><cell>(continued)</cell><cell></cell></row><row><cell></cell><cell>Patients</cell></row><row><cell>Characteristic</cell><cell>(N = 125)</cell></row><row><cell>Nectin-4 expression</cell><cell></cell></row><row><cell>level, H-scorek ¶</cell><cell></cell></row><row><cell>Median</cell><cell>290</cell></row><row><cell>Max, min</cell><cell>14, 300</cell></row><row><cell cols="2">NOTE. Data are represented as No. (%) unless otherwise indicated.</cell></row><row><cell cols="2">Abbreviations: ECOG, Eastern Cooperative Oncology Group; max,</cell></row><row><cell cols="2">maximum; min, minimum; PD-1/L1, programmed death 1 or</cell></row><row><cell>programmed death ligand 1.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>TABLE 3 .</head><label>3</label><figDesc>Summary of Adverse Events in Patients Receiving Enfortumab Vedotin</figDesc><table><row><cell>Variable</cell></row></table><note>*There were no treatment-related deaths during the 30-day safety reporting period. One death as a result of interstitial lung disease that occurred outside the safety reporting period was reported as treatment related.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>TABLE A1 .</head><label>A1</label><figDesc>Summary of Demographics and Disease Characteristics at</figDesc><table><row><cell>Baseline</cell><cell></cell></row><row><cell></cell><cell>Patients</cell></row><row><cell>Characteristic</cell><cell>(N = 125)</cell></row><row><cell>Age, years</cell><cell></cell></row><row><cell>Median</cell><cell>69</cell></row><row><cell>Min, max</cell><cell>40, 84</cell></row><row><cell>Age group, years</cell><cell></cell></row><row><cell>, 65</cell><cell>45 (36)</cell></row><row><cell>$ 65</cell><cell>80 (64)</cell></row><row><cell>, 75</cell><cell>91 (73)</cell></row><row><cell>$ 75</cell><cell>34 (27)</cell></row><row><cell>Sex</cell><cell></cell></row><row><cell>Male</cell><cell>88 (70)</cell></row><row><cell>Female</cell><cell>37 (30)</cell></row><row><cell>Race</cell><cell></cell></row><row><cell>White</cell><cell>106 (85)</cell></row><row><cell>Asian</cell><cell>11 (9)</cell></row><row><cell>Black or African American</cell><cell>2 (2)</cell></row><row><cell>Other</cell><cell>1 (1)</cell></row><row><cell>Not reportable</cell><cell>5 (4)</cell></row><row><cell>Region</cell><cell></cell></row><row><cell>North America</cell><cell>117 (94)</cell></row><row><cell>Asia</cell><cell>8 (6)</cell></row><row><cell>Ethnicity</cell><cell></cell></row><row><cell>Hispanic or Latino</cell><cell>5 (4)</cell></row><row><cell>Not Hispanic or Latino</cell><cell>118 (94)</cell></row><row><cell>Not reportable</cell><cell>2 (2)</cell></row><row><cell>Smoking status</cell><cell></cell></row><row><cell>Smoker a</cell><cell>82 (66)</cell></row><row><cell>Nonsmoker</cell><cell>43 (34)</cell></row><row><cell>Height, cm</cell><cell></cell></row><row><cell>Median</cell><cell>172.7</cell></row><row><cell>Min, max</cell><cell>146, 193</cell></row><row><cell>Weight, kg</cell><cell></cell></row><row><cell>Median</cell><cell>76.1</cell></row><row><cell>Min, max</cell><cell>45, 115</cell></row><row><cell>. 100</cell><cell>4 (3)</cell></row><row><cell>Body mass index, kg/m 2</cell><cell></cell></row><row><cell>Median</cell><cell>25.3</cell></row><row><cell>Min, max</cell><cell>17, 40</cell></row><row><cell>Body mass index, kg/m 2</cell><cell></cell></row><row><cell>, 25</cell><cell>58 (46)</cell></row><row><cell>25 to , 30</cell><cell>46 (37)</cell></row><row><cell>$ 30</cell><cell>21 (17)</cell></row><row><cell>(continued in next column)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>TABLE A1 .</head><label>A1</label><figDesc>Summary of Demographics and Disease Characteristics at</figDesc><table><row><cell>Baseline (continued)</cell><cell></cell></row><row><cell></cell><cell>Patients</cell></row><row><cell>Characteristic</cell><cell>(N = 125)</cell></row><row><cell>ECOG performance status, b</cell><cell></cell></row><row><cell>0</cell><cell>40 (32)</cell></row><row><cell>1</cell><cell>85 (68)</cell></row><row><cell>Primary tumor location</cell><cell></cell></row><row><cell>Bladder/other</cell><cell>81 (65)</cell></row><row><cell>Upper tract c</cell><cell>44 (35)</cell></row><row><cell>Histology type</cell><cell></cell></row><row><cell>Urothelial carcinoma only</cell><cell>84 (67)</cell></row><row><cell>Urothelial carcinoma with squamous</cell><cell>15 (12)</cell></row><row><cell>differentiation</cell><cell></cell></row><row><cell>Urothelial carcinoma with other histologic</cell><cell>26 (21)</cell></row><row><cell>variants</cell><cell></cell></row><row><cell>Time from diagnosis of metastatic disease to</cell><cell></cell></row><row><cell>enrollment, d months</cell><cell></cell></row><row><cell>No.</cell><cell>124</cell></row><row><cell>Median</cell><cell>15.4</cell></row><row><cell>Min, max</cell><cell>1, 85</cell></row><row><cell>Metastasis sites</cell><cell></cell></row><row><cell>Lymph nodes only</cell><cell>13 (10)</cell></row><row><cell>Visceral disease e</cell><cell>112 (90)</cell></row><row><cell>Bone</cell><cell>51 (41)</cell></row><row><cell>Liver</cell><cell>50 (40)</cell></row><row><cell>Lung</cell><cell>53 (42)</cell></row><row><cell>Renal function on the basis of creatinine clearance,</cell><cell></cell></row><row><cell>mL/min</cell><cell></cell></row><row><cell>Normal ($ 90)</cell><cell>26 (21)</cell></row><row><cell>Mild decrease ($ 60 and , 90)</cell><cell>51 (41)</cell></row><row><cell>Moderate decrease ($ 30 and , 60)</cell><cell>47 (38)</cell></row><row><cell>Severe decrease f ($ 15 and , 30)</cell><cell>1 (1)</cell></row><row><cell>HbA1c</cell><cell></cell></row><row><cell>No.</cell><cell>119</cell></row><row><cell>Median, %</cell><cell>5.60</cell></row><row><cell>Min, max, %</cell><cell>4.2, 7.2</cell></row><row><cell>Percent HbA1c</cell><cell></cell></row><row><cell>, 6.5</cell><cell>110 (88)</cell></row><row><cell>$ 6.5</cell><cell>9 (7)</cell></row><row><cell>Hemoglobin, g/dL</cell><cell></cell></row><row><cell>, 10</cell><cell>35 (28)</cell></row><row><cell>$ 10</cell><cell>89 (71)</cell></row><row><cell>Missing</cell><cell>1 (1)</cell></row><row><cell>(continued on following page)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>Search Term</cell></row><row><cell>Hyperglycemia</cell></row><row><cell>Acquired lipoatrophic diabetes</cell></row><row><cell>Blood 1,5-anhydroglucitol decreased</cell></row><row><cell>Blood glucose abnormal</cell></row><row><cell>Blood glucose fluctuation</cell></row><row><cell>Blood glucose increased</cell></row><row><cell>Diabetes complicating pregnancy</cell></row><row><cell>Diabetes mellitus</cell></row><row><cell>Diabetes mellitus inadequate control</cell></row><row><cell>Diabetes with hyperosmolarity</cell></row><row><cell>Diabetic arteritis</cell></row><row><cell>Diabetic coma</cell></row><row><cell>Diabetic hepatopathy</cell></row><row><cell>Diabetic hyperglycemic coma</cell></row><row><cell>Diabetic hyperosmolar coma</cell></row><row><cell>Diabetic ketoacidosis</cell></row><row><cell>Diabetic ketoacidotic hyperglycemic coma</cell></row><row><cell>Diabetic metabolic decompensation</cell></row><row><cell>Fructosamine increased</cell></row><row><cell>Fulminant type 1 diabetes mellitus</cell></row><row><cell>Gestational diabetes</cell></row><row><cell>Glucose tolerance impaired</cell></row><row><cell>Glucose tolerance impaired in pregnancy</cell></row><row><cell>Glucose urine present</cell></row><row><cell>Glycosuria</cell></row><row><cell>Glycosuria during pregnancy</cell></row><row><cell>Glycosylated hemoglobin increased</cell></row><row><cell>Hyperglycemia</cell></row><row><cell>Hyperglycemic hyperosmolar nonketotic syndrome</cell></row><row><cell>Hyperglycemic seizure</cell></row><row><cell>Hyperglycemic unconsciousness</cell></row><row><cell>Impaired fasting glucose</cell></row><row><cell>Insulin resistance</cell></row><row><cell>Insulin resistance syndrome</cell></row><row><cell>Insulin resistant diabetes</cell></row><row><cell>Insulin-requiring type 2 diabetes mellitus</cell></row><row><cell>Ketoacidosis</cell></row><row><cell>Ketonuria</cell></row><row><cell>Ketosis</cell></row><row><cell>Latent autoimmune diabetes in adults</cell></row><row><cell>Metabolic syndrome</cell></row><row><cell>Monogenic diabetes</cell></row><row><cell>Neonatal diabetes mellitus</cell></row><row><cell>(continued in next column)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Pancreatogenous diabetes</cell></row><row><cell>Type 1 diabetes mellitus</cell></row><row><cell>Type 2 diabetes mellitus</cell></row><row><cell>Type 3 diabetes mellitus</cell></row><row><cell>Urine ketone body present</cell></row><row><cell>Infusion-related reactions</cell></row><row><cell>Administration-related reaction</cell></row><row><cell>Administration site extravasation</cell></row><row><cell>Allergic reaction to excipient</cell></row><row><cell>Anaphylactic reaction</cell></row><row><cell>Anaphylactic shock</cell></row><row><cell>Anaphylactoid reaction</cell></row><row><cell>Anaphylactoid shock</cell></row><row><cell>Anaphylaxis treatment</cell></row><row><cell>Angioedema</cell></row><row><cell>Bronchospasm</cell></row><row><cell>Catheter site extravasation</cell></row><row><cell>Chemotherapy extravasation management</cell></row><row><cell>Documented hypersensitivity to administered product</cell></row><row><cell>Drug eruption</cell></row><row><cell>Drug hypersensitivity</cell></row><row><cell>Epiglottic edema</cell></row><row><cell>Extravasation</cell></row><row><cell>Face edema</cell></row><row><cell>Fixed eruption</cell></row><row><cell>Hypersensitivity</cell></row><row><cell>Immediate postinjection reaction</cell></row><row><cell>Implant site extravasation</cell></row><row><cell>Infusion related reaction</cell></row><row><cell>Infusion site abscess sterile</cell></row><row><cell>Infusion site anesthesia</cell></row><row><cell>Infusion site atrophy</cell></row><row><cell>Infusion site bruising</cell></row><row><cell>Infusion site calcification</cell></row><row><cell>Infusion site coldness</cell></row><row><cell>Infusion site cyst</cell></row><row><cell>Infusion site dermatitis</cell></row><row><cell>Infusion site discharge</cell></row><row><cell>Infusion site discoloration</cell></row><row><cell>Infusion site discomfort</cell></row><row><cell>Infusion site dryness</cell></row><row><cell>Infusion site dysesthesia</cell></row><row><cell>Infusion site eczema</cell></row><row><cell>(continued on following page)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Infusion site erosion</cell></row><row><cell>Infusion site erythema</cell></row><row><cell>Infusion site exfoliation</cell></row><row><cell>Infusion site extravasation</cell></row><row><cell>Infusion site fibrosis</cell></row><row><cell>Infusion site granuloma</cell></row><row><cell>Infusion site hematoma</cell></row><row><cell>Infusion site hemorrhage</cell></row><row><cell>Infusion site hyperesthesia</cell></row><row><cell>Infusion site hypersensitivity</cell></row><row><cell>Infusion site hypertrichosis</cell></row><row><cell>Infusion site hypertrophy</cell></row><row><cell>Infusion site hypoesthesia</cell></row><row><cell>Infusion site induration</cell></row><row><cell>Infusion site inflammation</cell></row><row><cell>Infusion site injury</cell></row><row><cell>Infusion site irritation</cell></row><row><cell>Infusion site ischemia</cell></row><row><cell>Infusion site joint discomfort</cell></row><row><cell>Infusion site joint effusion</cell></row><row><cell>Infusion site joint erythema</cell></row><row><cell>Infusion site joint inflammation</cell></row><row><cell>Infusion site joint movement impairment</cell></row><row><cell>Infusion site joint pain</cell></row><row><cell>Infusion site joint swelling</cell></row><row><cell>Infusion site joint warmth</cell></row><row><cell>Infusion site laceration</cell></row><row><cell>Infusion site lymphadenopathy</cell></row><row><cell>Infusion site macule</cell></row><row><cell>Infusion site mass</cell></row><row><cell>Infusion site mobility decreased</cell></row><row><cell>Infusion site necrosis</cell></row><row><cell>Infusion site nerve damage</cell></row><row><cell>Infusion site nodule</cell></row><row><cell>Infusion site edema</cell></row><row><cell>Infusion site pain</cell></row><row><cell>Infusion site pallor</cell></row><row><cell>Infusion site papule</cell></row><row><cell>Infusion site paresthesia</cell></row><row><cell>Infusion site phlebitis</cell></row><row><cell>Infusion site photosensitivity reaction</cell></row><row><cell>Infusion site plaque</cell></row><row><cell>Infusion site pruritus</cell></row><row><cell>(continued in next column)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_14"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Infusion site rash</cell></row><row><cell>Infusion site reaction</cell></row><row><cell>Infusion site recall reaction</cell></row><row><cell>Infusion site scab</cell></row><row><cell>Infusion site scar</cell></row><row><cell>Infusion site streaking</cell></row><row><cell>Infusion site swelling</cell></row><row><cell>Infusion site thrombosis</cell></row><row><cell>Infusion site ulcer</cell></row><row><cell>Infusion site urticaria</cell></row><row><cell>Infusion site vasculitis</cell></row><row><cell>Infusion site vesicles</cell></row><row><cell>Infusion site warmth</cell></row><row><cell>Injection-related reaction</cell></row><row><cell>Injection site extravasation</cell></row><row><cell>Laryngeal edema</cell></row><row><cell>Laryngospasm</cell></row><row><cell>Laryngotracheal edema</cell></row><row><cell>Lip swelling</cell></row><row><cell>Mast cell degranulation present</cell></row><row><cell>Medical device site extravasation</cell></row><row><cell>Pharyngeal edema</cell></row><row><cell>Red man syndrome</cell></row><row><cell>Stoma site extravasation</cell></row><row><cell>Swelling face</cell></row><row><cell>Swollen tongue</cell></row><row><cell>Symmetrical drug-related intertriginous and flexural exanthema</cell></row><row><cell>Throat tightness</cell></row><row><cell>Tongue edema</cell></row><row><cell>Type I hypersensitivity</cell></row><row><cell>Peripheral neuropathy</cell></row><row><cell>Acute painful neuropathy of rapid glycemic control</cell></row><row><cell>Acute polyneuropathy</cell></row><row><cell>Amyotrophy</cell></row><row><cell>Angiopathic neuropathy</cell></row><row><cell>Antiganglioside antibody positive</cell></row><row><cell>Antimyelin-associated glycoprotein antibodies positive</cell></row><row><cell>Antimyelin-associated glycoprotein associated polyneuropathy</cell></row><row><cell>Areflexia</cell></row><row><cell>Autoimmune neuropathy</cell></row><row><cell>Autonomic failure syndrome</cell></row><row><cell>Autonomic neuropathy</cell></row><row><cell>Axonal neuropathy</cell></row><row><cell>(continued on following page)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_15"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Biopsy peripheral nerve abnormal</cell></row><row><cell>Burning feet syndrome</cell></row><row><cell>Burning sensation</cell></row><row><cell>Decreased nasolabial fold</cell></row><row><cell>Decreased vibratory sense</cell></row><row><cell>Demyelinating polyneuropathy</cell></row><row><cell>Dysesthesia</cell></row><row><cell>Electromyogram abnormal</cell></row><row><cell>Formication</cell></row><row><cell>Gait disturbance</cell></row><row><cell>Genital hypoesthesia</cell></row><row><cell>Guillain-Barré syndrome</cell></row><row><cell>Hereditary motor and sensory neuropathy</cell></row><row><cell>Hypoesthesia</cell></row><row><cell>Hyporeflexia</cell></row><row><cell>Hypotonia</cell></row><row><cell>Ischemic neuropathy</cell></row><row><cell>Loss of proprioception</cell></row><row><cell>Miller Fisher syndrome</cell></row><row><cell>Mononeuritis</cell></row><row><cell>Mononeuropathy</cell></row><row><cell>Mononeuropathy multiplex</cell></row><row><cell>Motor dysfunction</cell></row><row><cell>Multifocal motor neuropathy</cell></row><row><cell>Muscle atrophy</cell></row><row><cell>Muscular weakness</cell></row><row><cell>Myelopathy</cell></row><row><cell>Nerve conduction studies abnormal</cell></row><row><cell>Nerve degeneration</cell></row><row><cell>Neuralgia</cell></row><row><cell>Neuritis</cell></row><row><cell>Neuromuscular pain</cell></row><row><cell>Neuromuscular toxicity</cell></row><row><cell>Neuromyopathy</cell></row><row><cell>Neuronal neuropathy</cell></row><row><cell>Neuropathic muscular atrophy</cell></row><row><cell>Neuropathy peripheral</cell></row><row><cell>Neuropathy vitamin B 6 deficiency</cell></row><row><cell>Neurotoxicity</cell></row><row><cell>Notalgia paraesthetica</cell></row><row><cell>Paresthesia</cell></row><row><cell>Paresthesia ear</cell></row><row><cell>Peripheral motor neuropathy</cell></row><row><cell>(continued in next column)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_16"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>Enfortumab Vedotin for Urothelial Carcinoma</cell></row><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Peripheral nerve lesion</cell></row><row><cell>Peripheral nerve palsy</cell></row><row><cell>Peripheral nerve paresis</cell></row><row><cell>Peripheral nervous system function test abnormal</cell></row><row><cell>Peripheral sensorimotor neuropathy</cell></row><row><cell>Peripheral sensory neuropathy</cell></row><row><cell>Peroneal nerve palsy</cell></row><row><cell>Phrenic nerve paralysis</cell></row><row><cell>Polyneuropathy</cell></row><row><cell>Polyneuropathy chronic</cell></row><row><cell>Polyneuropathy idiopathic progressive</cell></row><row><cell>Radiation neuropathy</cell></row><row><cell>Sensorimotor disorder</cell></row><row><cell>Sensory disturbance</cell></row><row><cell>Sensory loss</cell></row><row><cell>Skin burning sensation</cell></row><row><cell>Small fiber neuropathy</cell></row><row><cell>Synkinesis</cell></row><row><cell>Temperature perception test decreased</cell></row><row><cell>Tick paralysis</cell></row><row><cell>Tinel's sign</cell></row><row><cell>Toxic neuropathy</cell></row><row><cell>Ulnar neuritis</cell></row><row><cell>Vulvovaginal hypoesthesia</cell></row><row><cell>Rash</cell></row><row><cell>Acquired epidermolysis bullosa</cell></row><row><cell>Acute generalized exanthematous pustulosis</cell></row><row><cell>Autoimmune dermatitis</cell></row><row><cell>Blister</cell></row><row><cell>Blister rupture</cell></row><row><cell>Blood blister</cell></row><row><cell>Bromoderma</cell></row><row><cell>Bullous impetigo</cell></row><row><cell>Butterfly rash</cell></row><row><cell>Coma blister</cell></row><row><cell>Conjunctivitis</cell></row><row><cell>Corneal exfoliation</cell></row><row><cell>Cutaneous vasculitis</cell></row><row><cell>Dennie-Morgan fold</cell></row><row><cell>Dermatitis</cell></row><row><cell>Dermatitis allergic</cell></row><row><cell>Dermatitis atopic</cell></row><row><cell>Dermatitis bullous</cell></row><row><cell>(continued on following page)</cell></row><row><cell>Journal of Clinical Oncology</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_17"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Dermatitis contact</cell></row><row><cell>Dermatitis diaper</cell></row><row><cell>Dermatitis exfoliative</cell></row><row><cell>Dermatitis exfoliative generalized</cell></row><row><cell>Dermatitis herpetiformis</cell></row><row><cell>Diabetic bullosis</cell></row><row><cell>Drug eruption</cell></row><row><cell>Drug reaction with eosinophilia and systemic symptoms</cell></row><row><cell>Dyshidrotic eczema</cell></row><row><cell>Eczema</cell></row><row><cell>Eczema asteatotic</cell></row><row><cell>Eczema infantile</cell></row><row><cell>Eczema nummular</cell></row><row><cell>Eczema vesicular</cell></row><row><cell>Eczema weeping</cell></row><row><cell>Epidermal necrosis</cell></row><row><cell>Epidermolysis</cell></row><row><cell>Epidermolysis bullosa</cell></row><row><cell>Erythema</cell></row><row><cell>Erythema ab igne</cell></row><row><cell>Erythema elevatum diutinum</cell></row><row><cell>Erythema multiforme</cell></row><row><cell>Erythema toxicum neonatorum</cell></row><row><cell>Exfoliative rash</cell></row><row><cell>Fixed eruption</cell></row><row><cell>Flagellate dermatitis</cell></row><row><cell>Fracture blisters</cell></row><row><cell>Generalized erythema</cell></row><row><cell>Genital ulceration</cell></row><row><cell>Hand dermatitis</cell></row><row><cell>Herpes gestationis</cell></row><row><cell>HLA-B*1502 assay positive</cell></row><row><cell>HLA-B*5801 assay positive</cell></row><row><cell>Hypopharyngeal synechiae</cell></row><row><cell>Intertrigo</cell></row><row><cell>Linear IgA disease</cell></row><row><cell>Lip exfoliation</cell></row><row><cell>Lupus miliaris disseminatus faciei</cell></row><row><cell>Mazzotti reaction</cell></row><row><cell>Morbihan disease</cell></row><row><cell>Mouth ulceration</cell></row><row><cell>Mucocutaneous rash</cell></row><row><cell>Mucocutaneous ulceration</cell></row><row><cell>(continued in next column)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_18"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Mucosa vesicle</cell></row><row><cell>Mucosal erosion</cell></row><row><cell>Mucosal exfoliation</cell></row><row><cell>Mucosal necrosis</cell></row><row><cell>Mucosal ulceration</cell></row><row><cell>Necrolytic migratory erythema</cell></row><row><cell>Neurodermatitis</cell></row><row><cell>Nikolsky's sign</cell></row><row><cell>Nodular rash</cell></row><row><cell>Noninfective conjunctivitis</cell></row><row><cell>Occupational dermatitis</cell></row><row><cell>Oculomucocutaneous syndrome</cell></row><row><cell>Oral mucosal blistering</cell></row><row><cell>Oral mucosal exfoliation</cell></row><row><cell>Oral papule</cell></row><row><cell>Oropharyngeal blistering</cell></row><row><cell>Palmar erythema</cell></row><row><cell>Palmar-plantar erythrodysaesthesia syndrome</cell></row><row><cell>Paraneoplastic pemphigus</cell></row><row><cell>Paraneoplastic rash</cell></row><row><cell>Pemphigoid</cell></row><row><cell>Pemphigus</cell></row><row><cell>Penile exfoliation</cell></row><row><cell>Periarticular thenar erythema with onycholysis</cell></row><row><cell>Perivascular dermatitis</cell></row><row><cell>Plantar erythema</cell></row><row><cell>Prurigo</cell></row><row><cell>Pseudocellulitis</cell></row><row><cell>Pseudoporphyria</cell></row><row><cell>Rash</cell></row><row><cell>Rash erythematous</cell></row><row><cell>Rash generalized</cell></row><row><cell>Rash macular</cell></row><row><cell>Rash maculo-papular</cell></row><row><cell>Rash maculovesicular</cell></row><row><cell>Rash morbilliform</cell></row><row><cell>Rash neonatal</cell></row><row><cell>Rash papular</cell></row><row><cell>Rash rubelliform</cell></row><row><cell>Rash scarlatiniform</cell></row><row><cell>Rash vesicular</cell></row><row><cell>Rebound atopic dermatitis</cell></row><row><cell>Rebound eczema</cell></row><row><cell>(continued on following page)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_19"><head>TABLE A5 .</head><label>A5</label><figDesc>Search Terms Used for Composite Adverse Events Listed are all search terms used to identify events considered to be indicative of hyperglycemia, infusion-related reactions, peripheral neuropathy, or rash on the basis of standardized terms in the Medical Dictionary for Regulatory Activities (version 20.0).</figDesc><table><row><cell>(continued)</cell></row><row><cell>Search Term</cell></row><row><cell>Red man syndrome</cell></row><row><cell>Sea bather's eruption</cell></row><row><cell>Seborrhoeic dermatitis</cell></row><row><cell>Skin erosion</cell></row><row><cell>Skin exfoliation</cell></row><row><cell>Skin irritation</cell></row><row><cell>Skin necrosis</cell></row><row><cell>Staphylococcal scalded skin syndrome</cell></row><row><cell>Stasis dermatitis</cell></row><row><cell>Stevens-Johnson syndrome</cell></row><row><cell>Stomatitis</cell></row><row><cell>Symmetrical drug-related intertriginous and flexural exanthema</cell></row><row><cell>Systemic lupus erythematosus rash</cell></row><row><cell>Tongue exfoliation</cell></row><row><cell>Toxic epidermal necrolysis</cell></row><row><cell>Toxic erythema of chemotherapy</cell></row><row><cell>Toxic skin eruption</cell></row><row><cell>Transient neonatal pustular melanosis</cell></row><row><cell>Umbilical erythema</cell></row><row><cell>Vaginal exfoliation</cell></row><row><cell>Vaginal ulceration</cell></row><row><cell>Vulval ulceration</cell></row><row><cell>Vulvovaginal rash</cell></row><row><cell>Vulvovaginal ulceration</cell></row><row><cell>NOTE.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_20"><head>TABLE A6 .</head><label>A6</label><figDesc>Summary of Time to Onset, Improvement, and Resolution for Treatment-Related Adverse Events of Interest</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Median Time to Onset of</cell><cell>Median Time to Improvement</cell><cell>Median Time to Resolution</cell></row><row><cell></cell><cell>No. of Patients With</cell><cell>Total No. of</cell><cell>First Event,*</cell><cell>of Any Event, †</cell><cell>of Any Event, ‡</cell></row><row><cell>Adverse Event</cell><cell>Any-Grade Event</cell><cell>Any-Grade Events*</cell><cell>Months (range)</cell><cell>Months (range)</cell><cell>Months (range)</cell></row><row><cell>Peripheral</cell><cell>63</cell><cell>80</cell><cell>2.43 (0.03-7.39)</cell><cell>1.18 (0.26-4.86)</cell><cell>1.48 (0.23-11.60)</cell></row><row><cell>neuropathy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rash</cell><cell>60</cell><cell>110</cell><cell>0.53 (0.03-7.39)</cell><cell>0.72 (0.03-2.66)</cell><cell>0.72 (0.03-7.20)</cell></row><row><cell>Hyperglycemia</cell><cell>14</cell><cell>16</cell><cell>0.58 (0.26-9.23)</cell><cell>0.89 (0.59-1.18)</cell><cell>1.12 (0.26-6.47)</cell></row></table><note>*Patients could have had more than one event.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Enfortumab Vedotin for Urothelial Carcinoma</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2019 by American Society of Clinical OncologyVolume 37, Issue 29</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Accountable for all aspects of the work: All authors ACKNOWLEDGMENT Writing assistance was provided by Heather Brignull, PhD, and Candice L. Willmon, PhD, of Seattle Genetics.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST APPENDIX</head><p>This appendix has been provided by the authors to give readers additional information about their work.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EV-201 Investigators</head><p>The following investigators (listed by country) participated in the EV-201 study:  ECOG performance status scale ranges from 0 to 5, with 0 indicating that the patient is fully active with no restrictions, 1 that the patient is ambulatory and able to carry out work of a light or sedentary nature but restricted in physically strenuous activity, and higher numbers indicating greater disability. Bellmunt risk factors include ECOG performance status . 0, hemoglobin , 10 g/dL, and presence of liver metastasis. <ref type="bibr" target="#b25">21</ref> h Including PD-1/L1-containing therapy in the neoadjuvant/adjuvant setting with progression or recurrence within 3 months after therapy completion, or platinum-based therapy in the neoadjuvant/adjuvant setting with progression or recurrence within 12 months after therapy conclusion.  Progressive disease 17 <ref type="bibr" target="#b18">(14)</ref> Not evaluable ‡ 11 <ref type="bibr" target="#b13">(9)</ref> NOTE. Data are presented as No. (%). *CI was computed using the Clopper-Pearson method. <ref type="bibr" target="#b26">22</ref> †Best overall response according to RECIST v1.1. ‡Includes 10 patients who did not have any response assessment postbaseline and one patient whose postbaseline assessment did not meet the minimum interval requirement for stable disease.  </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Sloan Kettering Cancer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Center</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Petrylak Provision of study material or patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">York</forename><surname>Ave</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">10065; e-mail: rosenbj1@mskcc.org. SUPPORT Supported by Seattle Genetics and Astellas Pharma. design: Jonathan E</title>
		<editor>Jonathan E. Rosenberg, Peter H</editor>
		<meeting><address><addrLine>New York, NY</addrLine></address></meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">Petrylak Collection and assembly of data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arjun</forename><forename type="middle">V</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bradley</forename><forename type="middle">A</forename><surname>Balar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisabeth</forename><forename type="middle">I</forename><surname>Mcgregor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><forename type="middle">Y</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noah</forename><forename type="middle">M</forename><surname>Galsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Daniel</surname></persName>
		</author>
		<imprint>
			<pubPlace>Jonathan E. Rosenberg, Peter H</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Petrylak Data analysis and interpretation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arjun</forename><forename type="middle">V</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bradley</forename><forename type="middle">A</forename><surname>Balar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisabeth</forename><forename type="middle">I</forename><surname>Mcgregor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><forename type="middle">Y</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noah</forename><forename type="middle">M</forename><surname>Galsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elaina</forename><forename type="middle">M</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Juan</forename><forename type="middle">M</forename><surname>Gartner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shang-Ying</forename><surname>Pinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Liang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Amal Melhem-Bertrandt</title>
		<imprint>
			<publisher>Daniel P</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arjun</forename><forename type="middle">V</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bradley</forename><forename type="middle">A</forename><surname>Balar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisabeth</forename><forename type="middle">I</forename><surname>Mcgregor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Heath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Evan</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Petrylak Manuscript writing: All authors Final approval of manuscript: All authors REFERENCES 1. National Cancer Institute: SEER Cancer Stat Facts: Bladder Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noah</forename><forename type="middle">M</forename><surname>Galsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elaina</forename><forename type="middle">M</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Juan</forename><forename type="middle">M</forename><surname>Gartner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shang-Ying</forename><surname>Pinelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amal</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Melhem-Bertrandt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Daniel</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2019" />
			<pubPlace>Bethesda, MD, National Cancer Institute</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Von Der Maase</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">T</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3068" to="3077" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">De</forename><surname>Santis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Mead</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="191" to="199" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Der Maase</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">M</forename><surname>Mead</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1107" to="1113" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Pembrolizumab as second-line therapy for advanced urothelial carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Vaughn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="1015" to="1026" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Powles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Durán</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Van Der Heijden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">391</biblScope>
			<biblScope unit="page" from="748" to="757" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Bladder cancer (version .2</title>
		<ptr target="https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf" />
		<imprint>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Challita-Eid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Satpayev</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="3003" to="3013" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">O</forename><surname>Doronina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">E</forename><surname>Toki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Y</forename><surname>Torgov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotechnol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">941</biblScope>
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>Nat Biotechnol</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Nectins and nectin-like molecules in development and disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Mandai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Rikitake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Top Dev Biol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="197" to="231" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Takai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Ogita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Cell Dev Biol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="309" to="342" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Nectins and nectin-like molecules: Roles in contact inhibition of cell movement and proliferation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Takai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Miyoshi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Ikeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="603" to="615" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">High expression of nectin-4 is associated with unfavorable prognosis in gastric cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Lett</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="8789" to="8795" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Membranous nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Lattanzio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ghasemi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Brancati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogenesis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">118</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Takano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nishino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="6694" to="6703" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">A role for PVRL4-driven cell-cell interactions in tumorigenesis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">N</forename><surname>Pavlova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Pallasch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">E</forename><surname>Elia</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013" />
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">358</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Sridhar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Perez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
	<note>abstr 788P</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bogaerts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="228" to="247" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Vaughn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Broome</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hussain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="937" to="940" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Choueiri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Fougeray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1850" to="1855" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The use of confidence or fiducial limits illustrated in the case of the binomial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Clopper</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">S</forename><surname>Pearson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="404" to="413" />
			<date type="published" when="1934" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Drakaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Kirby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Van Der Heijden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
	<note>abstr 434</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Clinical toxicity of antibody drug conjugates: A meta-analysis of payloads</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Masters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Nickens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Xuan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Yohann Loriot; Germany: Jens Bedke; Italy: Andrea Necchi</title>
		<imprint>
			<date type="published" when="2018" />
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="121" to="135" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Satoshi</forename><surname>Japan: Satoshi Fukasawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yasuhiro</forename><surname>Fukasawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Junichi</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiro-Omi</forename><surname>Inokuchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takahiro</forename><surname>Kanayama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryuichi</forename><surname>Kojima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kazuo</forename><surname>Mizuno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wataru</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihiko</forename><surname>Obara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshiaki</forename><surname>Tomita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Yamamoto</surname></persName>
		</author>
		<title level="m">Akira Yokomizo, and Kazuhiro Yoshimura; the Netherlands: Michiel van der Heijden</title>
		<editor>South Korea: Yu Jung Kim, Hyo Jin Lee, Jae Lyun Lee, Se Hoon Park, and Sang Joon Shin</editor>
		<meeting><address><addrLine>Spain</addrLine></address></meeting>
		<imprint/>
	</monogr>
	<note>Ignacio Duran</note>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leonard</forename><surname>Appleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arjun</forename><surname>Balar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Britt</forename><surname>Bolemon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jorge</forename><surname>Darcourt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nancy</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><surname>Disimone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Dreicer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicholas</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chunkit</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><surname>Galsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noah</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisabeth</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nataliya</forename><surname>Mar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bradley</forename><surname>Mcgregor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Megan</forename><surname>Mcnamara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amir</forename><surname>Mortazavi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><surname>Myrick ; David</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Parminder</forename><surname>Shaffer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicholas</forename><surname>Suga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><surname>Vogelzang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Evan</forename><surname>Yorio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingsong</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Zhang</surname></persName>
		</author>
		<imprint>
			<pubPlace>Peter O&apos;Donnell, Moshe Ornstein, Chong-Xian Pan, Daniel Petrylak, Joel Picus, David Quinn, Arash Rezazadeh, Jonathan Rosenberg Ian Schnadig</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
